Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Br-
-methyl-phenylalanine for tumor PET imagingHanaoka, Hirofumi*; Ohshima, Yasuhiro; Suzuki, Yurika*; Yamaguchi, Aiko*; Watanabe, Shigeki; Uehara, Tomoya*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Ishioka, Noriko; Tsushima, Yoshito*; et al.
Journal of Nuclear Medicine, 56(5), p.791 - 797, 2015/05
Times Cited Count：18 Percentile：62.62(Radiology, Nuclear Medicine & Medical Imaging)Shigyo, Nobuhiro*; Uozumi, Yusuke*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Mizuno, Takafumi*; Takamiya, Masanori*; Hashiguchi, Taro*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; et al.
Nuclear Data Sheets, 119, p.303 - 306, 2014/05
Times Cited Count：0 Percentile：0.02(Physics, Nuclear)Heavy ion cancer therapy has been increased by reason of its clinical advantages. During the treatment, the secondary particles such as neutron and 
-ray are produced by nuclear reactions of a heavy ion incidence on a nucleus in a patient body. Estimation of the secondary neutrons yields data is essential for assessment of radiation safety on both of workers and public in treatment facilities. We have measured the neutron yields from carbon ion incidence on carbon, nitrogen and oxygen targets in wide angular range from 15
to 90 with 100- and 290-MeV/u.
Shigyo, Nobuhiro*; Uozumi, Yusuke*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Hirabayashi, Keiichi*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; Takada, Masashi*; Matsufuji, Naruhiro*
Progress in Nuclear Science and Technology (Internet), 4, p.709 - 712, 2014/04
Heavy ion cancer therapy has been increased by reason of its clinical advantages. During the treatment, the secondary particles such as neutron and -ray are produced by nuclear reactions of a heavy ion incidence on a nucleus in a patient body. Estimation of the secondary neutrons yields data is essential for assessment of radiation safety on both of workers and public in treatment facilities. Neutron energy spectra from a water phantom simulating the patient body were obtained at GSI only for forward directions. We measured the neutron yields from carbon ion incident on a water phantom in wide angular range from 15 to 90 with the therapeutic ion energy.
Shigyo, Nobuhiro*; Uozumi, Yusuke*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Mizuno, Takafumi*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; Takada, Masashi*; Matsufuji, Naruhiro*
JAEA-Conf 2013-002, p.137 - 142, 2013/10
Heavy ion cancer therapy has been increased by reason of its clinical advantages. During the treatment, the secondary particles such as neutron and -ray are produced by nuclear reactions of a heavy ion incidence on a nucleus in a patient body. Estimation of double differential cross sections of secondary neutron is important to risk assessment of extra dose to organs in the vicinity of the irradiated tumor. Accurate data in neutron energy around 1 MeV is required because neutron in the energy region has large relative biological effectiveness. Neutron double differential cross sections by inducing 290 MeV/u carbon ion to bio-elements have been obtained experimentally. In order to have knowledge of neutron production by deceleration carbon in a human body, we measured the neutron yields from carbon ion incidence on a carbon target of neutron energy below 1 MeV in wide angular range from 15 to 90 with 100 MeV/u.
Uozumi, Yusuke*; Shigyo, Nobuhiro*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Mizuno, Takafumi*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; Takada, Masashi*; Matsufuji, Naruhiro*; et al.
HIMAC-140, p.234 - 235, 2013/08
In the heavy-ion radiotherapy, considerable discussion has been attracted regarding the potential for second cancer induction by secondary neutrons produced from the primary heavy-ion fragmentation. We have started new measurements at 100 MeV/u to investigate the neutron production by heavy ions decelerating in a patient body.
Uozumi, Yusuke*; Shigyo, Nobuhiro*; Kajimoto, Tsuyoshi*; Hirabayashi, Keiichi*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; Takada, Masashi*; et al.
HIMAC-138, p.237 - 238, 2012/08
In the heavy-ion radiotherapy, considerable discussion has been attracted regarding the potential for second cancer induction by secondary neutrons produced from the primary heavy-ion fragmentation. It is important to measure energy-angle double-differential cross sections (DDXs) of neutron- and photon-productions in heavy-ion nuclear reactions. Since it is notoriously hard to measure the spectral cross sections of neutrons in an energy range of around 1 MeV where the RBE value reaches at its maximum. In the project by last year, experiments were carried out at the synchrotron HIMAC of NIRS, Japan. The beams were 
C and 
O of 290 MeV/u and bombarded a carbon target. In measurements of neutrons and photons were used liquid scintillator detectors of 5" and 2". We have succeeded to lower the neutron energy threshold down to 0.6 MeV. The present results for neutron productions are in reasonable agreements with PHITS. Since our goal in technical aspects has been fulfilled, measurements will be continued for other reactions.
Re]Organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levelsUehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Hashimoto, Kazuyuki; Akizawa, Hiromichi*; Endo, Keigo*; Arano, Yasushi*
Bioconjugate Chemistry, 18(1), p.190 - 198, 2007/01
Times Cited Count：20 Percentile：55.24(Biochemical Research Methods)Renal localization of radiolabeled antibody fragments constitutes a problem in targeted imaging and radiotherapy. To estimate the applicability of the molecular design to metallic radionuclides, [Re]tricarbonyl(cyclopentadienylcarbonate)rhenium ([Re]CpTR-COOH) was conjugated with maleoyl-glycyl-lysine to prepare [Re]CpTR-GK. The cleavage of the glycyl-lysine linkage of the compound generates a glycine conjugate of [Re]CpTR-Gly. [Re]CpTR-GK was conjugated to thiolated Fab fragments to prepare [Re]CpTR-GK-Fab. The biodistribution of radioactivity after injection of [Re]CpTR-GK-Fab was compared with that of [Re]CpTR-Fab. [Re]CpTR-GK-Fab exhibited significantly lower renal radioactivity levels than did [Re]CpTR-Fab. The analysis of urine samples collected for 6 h postinjection of [Re]CpTR-GK-Fab showed that [Re]CpTR-Gly was the major radiometabolite. In tumor-bearing mice, [Re]CpTR-GK-Fab significantly reduced renal radioactivity levels without impairing the radioactivity levels in tumor. These findings indicate that the molecular design of radioparmaceuticals labeled with metallic radionuclides can be useful by using a radiometal chelate of high inertness and by designing a radiometabolite of high urinary excretion when released from antibody fragments following cleavage of a glycyl-lysine linkage. This study also indicates that a change in chemical structure of a radiolabel attached to a glycyl-lysine linkage significantly affected enzymes involved in the hydrolysis reaction.
Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bonesUehara, Tomoya*; Jin, Z. L.*; Ogawa, Kazuma*; Akizawa, Hiromichi*; Hashimoto, Kazuyuki; Nakayama, Morio*; Arano, Yasushi*
Nuclear Medicine and Biology, 34(1), p.79 - 87, 2007/01
Times Cited Count：23 Percentile：56.61(Radiology, Nuclear Medicine & Medical Imaging)In this study, a key factor affecting the pharmacokinetics of a chelate-conjugated BP was investigated to estimate the validity and the applicability of molecular design. Chemically inert and well-characterized [Re]CpTR-Gly was conjugated with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate and purified by HPLC to prepare [Re]CpTR-Gly-APD. Plasma stability, plasma protein binding, hydroxyapatite (HA) binding and the pharmacokinetics of [Re]CpTR-Gly-APD were compared with those of Re 1-hydroxyethylidene-1,1-diphosphonate (HEDP). The HPLC-purified [Re]CpTR-Gly-APD showed higher plasma stability, higher HA binding, higher bone accumulation and lower plasma protein binding than did Re -HEDP. Although Re -HEDP possessed HA binding and bone accumulation similar to those of [Re]CpTR-Gly-APD, the specific activity of Re -labeled BPs was found to play a crucial role in bone accumulation and blood clearance. Thus, the molecular design of chelate-conjugated BP would be useful for the development of bone-seeking radiopharmaceuticals with a variety of radionuclides by selecting chelating molecules that provide high specific activities.
Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Otaka, Akira*; Ueda, Masashi*; Uehara, Tomoya*; Magata, Yasuhiro*; Hashimoto, Kazuyuki; Saji, Hideo*
Nuclear Medicine and Biology, 33(4), p.513 - 520, 2006/05
Times Cited Count：54 Percentile：80.16(Radiology, Nuclear Medicine & Medical Imaging)To develop a radiopharmaceutical for the palliation of painful bone metastases based on the concept of bifunctional radiopharmaceuticals, we synthesized a bisphosphonate derivative labeled with rhenium-186 (Re) that contains a hydroxyl group at the central carbon of its bisphosphonate structure and attached a stable Re-MAMA chelate to the amino group of a 4-amino-butylidene-bisphosphonate derivative, Re-MAMA-HBP, and investigated the effect of a hydroxyl group at the central carbon of its bisphosphonate structure on the affinity for hydroxyapatite and biodistribution by conducting a comparative study with Re-MAMA-BP. Re-MAMA-HBP was prepared by a reaction with ReO
and SnCl
in citrate buffer after the deprotection of trityl groups of Tr-MAMA-HBP. After reversed phase HPLC, Re-MAMA-HBP had a radiochemical purity of over 95 %. Compared with Re-MAMA-BP, Re-MAMA-HBP showed a greater affinity for hydroxyapatite beads in vitro and accumulated a significantly higher level in the femur in vivo. Thus, the introduction of a hydroxyl group into Re complex-conjugated bisphosphonates would be effective in enhancing accumulation in bone. These findings provide useful information on the design of bone-seeking therapeutic radiopharmaceuticals.
Uehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Miyamoto, Shigehiko*; Motoishi, Shoji; Hashimoto, Kazuyuki; Oku, Naoto*; Nakayama, Morio*; Arano, Yasushi*
Nuclear Medicine and Biology, 30(3), p.327 - 334, 2003/04
Times Cited Count：20 Percentile：50.16(Radiology, Nuclear Medicine & Medical Imaging)no abstracts in English
Ogawa, Kazuma*; Ono, Masahiro*; Fujioka, Yasushi*; Saji, Hideo*; Mukai, Takahiro*; Konishi, Junji*; Uehara, Tomoya*; Arano, Yasushi*; Onoma, Katsuyuki
Kaku Igaku, 37(5), P. 577, 2000/09
no abstracts in English
Tc and 
ReKiyota, Sachiko*; Uehara, Tomoya*; Ishii, Daisuke*; Akizawa, Hiromichi*; Hashimoto, Kazuyuki; Arano, Yasushi*
no journal, ,
no abstracts in English
Br-labeled antibody fragments for reduction of non-target radioactivityHanaoka, Hirofumi*; Watanabe, Shigeki; Watanabe, Satoshi; Ohshima, Yasuhiro; Uehara, Tomoya*; Akizawa, Hiromichi*; Iida, Yasuhiko*; Ishioka, Noriko; Arano, Yasushi*; Endo, Keigo*
no journal, ,
no abstracts in English
Shigyo, Nobuhiro*; Uozumi, Yusuke*; Uehara, Haruhiko*; Nishizawa, Tomoya*; Hirabayashi, Keiichi*; Satoh, Daiki; Sanami, Toshiya*; Koba, Yusuke*; Takada, Masashi*; Matsufuji, Naruhiro*
no journal, ,
Heavy ion cancer therapy has been increased by reason of its clinical advantages. During the treatment, the secondary particles such as neutron and -ray are produced by nuclear reactions of a heavy ion incidence on a nucleus in a patient body. Estimation of the secondary neutrons yields data is essential for assessment of radiation safety on both of workers and public in treatment facilities. Neutron energy spectra from a water phantom simulating the patient body were obtained at GSI only for forward directions. We measured the neutron yields from carbon ion incident on a water phantom in wide angular range from 15
to 90 with the therapeutic ion energy.
evaluation of 
In labeled hippuric acid derivative with high urinary excretionSuzuki, Hiroyuki; Kanai, Ayaka*; Uehara, Tomoya*; Hanaoka, Hirofumi*; Arano, Yasushi*
no journal, ,
Br-bromo--methyl-L-phenylalanine as a novel Br-labeled PET tracerOhshima, Yasuhiro; Hanaoka, Hirofumi*; Suzuki, Yurika*; Yamaguchi, Aiko*; Watanabe, Shigeki; Uehara, Tomoya*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Ishioka, Noriko; Tsushima, Yoshito*; et al.
no journal, ,
no abstracts in English
